James J Ignatz-Hoover

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Multiple Myeloma

Histone Deacetylase

Top Venues

Cancer research communications

Nature communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Priyanka S Rana, James J Ignatz-Hoover, Byung-Gyu Kim, Ehsan Malek, Yuriy Fedorov, Drew J Adams, Timothy A Chan, James J Driscoll
HDAC6 inhibition releases HR23B to activate proteasomes, expand the tumor immunopeptidome and amplify T-cell antimyeloma activity. Cancer research communications (2024)
Ehsan Malek, Priyanka S Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J Ignatz-Hoover, Leland Metheny, Seong Jin Kim, James J Driscoll
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial. Nature communications 15 (1) (2024)
Priyanka S Rana, James J Ignatz-Hoover, Byung-Gyu Kim, Ehsan Malek, Yuriy Fedorov, Drew J Adams, Timothy A Chan, James J Driscoll
HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity. Cancer research communications 4 (6) (2024)
Priyanka S Rana, James J Ignatz-Hoover, Byung-Gyu Kim, Ehsan Malek, Yuriy Fedorov, Drew J Adams, Timothy A Chan, James J Driscoll
HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity. Cancer research communications 4 (6) (2024)
Ehsan Malek, Priyanka S Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J Ignatz-Hoover, Leland Metheny, Seong Jin Kim, James J Driscoll
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial. Nature communications 15 (1) (2024)
Ehsan Malek, Priyanka S Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J Ignatz-Hoover, Leland Metheny, Seong Jin Kim, James J Driscoll
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial. Nature communications 15 (1) (2024)
Priyanka S Rana, James J Ignatz-Hoover, Byung-Gyu Kim, Ehsan Malek, Yuriy Fedorov, Drew J Adams, Timothy A Chan, James J Driscoll
HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity. Cancer research communications 4 (6) (2024)
Priyanka S Rana, James J Ignatz-Hoover, Byung-Gyu Kim, Ehsan Malek, Yuriy Fedorov, Drew J Adams, Timothy A Chan, James J Driscoll
HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity. Cancer research communications 4 (6) (2024)
Ehsan Malek, Priyanka S Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J Ignatz-Hoover, Leland Metheny, Seong Jin Kim, James J Driscoll
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial. Nature communications 15 (1) (2024)
Priyanka S Rana, James J Ignatz-Hoover, Chunna Guo, Amber L Mosley, Ehsan Malek, Yuriy Fedorov, Drew J Adams, James J Driscoll
Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens and enhances T-cell antimyeloma activity. Molecular cancer therapeutics (2024)
Priyanka S Rana, James J Ignatz-Hoover, Byung-Gyu Kim, Ehsan Malek, Yuriy Fedorov, Drew J Adams, Timothy A Chan, James J Driscoll
HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity. Cancer research communications 4 (6) (2024)
James J Ignatz-Hoover, Victoria Wang, Nathan M Mackowski, Anne J Roe, Isaac K Ghansah, Masumi Ueda, Hillard M Lazarus, Marcos de Lima, Elisabeth Paietta, Hugo Fernandez, Larry Cripe, Martin Tallman, David N Wald
Aberrant GSK3β nuclear localization promotes AML growth and drug resistance. Blood advances 2 (21) (2019)